Avutometinib + Adagrasib for Lung Cancer

(RAMP204 Trial)

This trial tests a new combination of two drugs, avutometinib (a Raf/MEK inhibitor) and adagrasib (also known as Krazati), to determine their safety and effectiveness for people with G12C Non-Small Cell Lung Cancer (NSCLC). The focus is on patients whose cancer has continued to grow despite other G12C inhibitor treatments. It suits those with the KRAS G12C mutation who have undergone some, but not excessive, prior treatments. Participants should have manageable health conditions and be able to take oral medications. As a Phase 1, Phase 2 trial, this study aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking research.

The trial requires you to stop taking certain medications, like strong CYP3A4 inhibitors or inducers, and strong inhibitors of breast cancer resistance protein (BCRP), at least 14 days before starting the study. If you're on these medications, you may need to discuss alternatives with your doctor.

Research shows that the drugs avutometinib (VS-6766) and adagrasib are being tested together to assess their safety for people with lung cancer. Earlier studies with similar drug combinations have shown promising results. Most patients have tolerated the treatments well. Some side effects have been reported, but they are usually mild to moderate.

Common side effects might include fatigue, nausea, or mild skin rashes, which are typical for cancer treatments. Importantly, studies involving avutometinib have not commonly reported severe or life-threatening effects.

Researchers are excited about the combination of Avutometinib (VS-6766) and Adagrasib for lung cancer because these drugs target cancer cells in a novel way. Unlike standard treatments that may focus on broad chemotherapy or radiation, Avutometinib plus Adagrasib specifically aim at inhibiting the KRAS G12C mutation, a common driver in certain lung cancers. This targeted approach could potentially improve outcomes for patients who have previously been exposed to G12C inhibitors by directly disrupting the cancer's growth signals. The specificity of this mechanism offers hope for more effective and personalized cancer therapies.

Research has shown that combining two drugs, avutometinib (VS-6766) and adagrasib, may help treat G12C Non-Small Cell Lung Cancer (NSCLC). Avutometinib blocks proteins that promote cancer cell growth, while adagrasib targets a specific mutation in the cancer cells called KRAS G12C, common in this type of lung cancer. This trial will assess the effectiveness of this combination in patients previously exposed to G12C inhibitors. Studies have found that these drugs together can halt cancer cell growth in patients who have tried other treatments. Early results suggest this combination could be a promising treatment option for patients with this mutation.¹³⁴⁶⁷